Bio-Rad Laboratories, Inc. BIO posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks ...

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

Tensions at Manhattan's immigration courts are reaching a boiling point. Last week, Immigration and Customs Enforcement reinstated the officer who was initially relieved of duties after shoving an ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...

VQ-101 is the first small molecule to demonstrate >70% activation of the lysosomal enzyme glucocerebrosidase (GCase) in GBA-Parkinson’s (GBA-PD) patients In the ongoing Phase 1b study in patients with ...

Banking giant JPMorgan says bitcoin BTC $113,335.37 could climb to around $165,000 on a volatility-adjusted basis relative to gold, highlighting what the bank sees as significant upside if the ...

Pharma companies are collaborating to boost the power of artificial intelligence (AI) in drug discovery by allowing access to proprietary structural data to train a large language model. Each of the ...

Oct 1 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab, Takeda Pharmaceuticals (4502.T), opens new tab and Astex Pharmaceuticals are coming together to share proprietary data for training an ...

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with ...

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up ...